Introduction
============

An enduring, but incomplete observation in MDD (Major Depressive Disorder) is of serotonin dysfunction. Serotonin dysfunction is a corollary of the monoamine hypothesis, positing that MDD is associated with relative depletion of monoamines including catecholamines (e.g., dopamine and noradrenaline) and tryptamine (e.g., serotonin) ([@B144]). Parallel and sometimes convergent reports spanning neurochemistry, behavioral pharmacology, neuroimaging and gene have implicated serotonergic dysfunction in MDD. However, while such dysfunction can be thought of as a typical, it is very clearly not a universal characteristic of MDD ([@B2]; [@B50]; [@B133]). Evidence that serotonin function is relevant in a subset of those with MDD includes a number of different avenues of exploration. First, affective experience and emotional regulation are more dramatically altered after acute tryptophan depletion (ATD), more so in persons with personal or family history of MDD ([@B113]; [@B28]; [@B95]; [@B130]; [@B138]). Second, selective serotonergic reuptake inhibitors (SSRIs) are more effective than placebo in a majority of controlled clinical trials ([@B116]; [@B137]). Third, functional loci at genes that mediate serotonergic function have been implicated in MDD both alone, and via interaction with early life stress ([@B36], [@B35]; [@B124]; [@B95]; [@B133]; [@B29]; [@B86]). Fourth, some of these functional variants in genes (modulating serotonin function) alter brain responses to emotion and brain connectivity ([@B21]; [@B51]; [@B26]; [@B143]). These alternations align with a model of how inherited variations contribute to risk for MDD. Fifth, manipulations of serotonin function and/or use of agents with serotonergic effects within animal models can simulate depression and anxiety-like behaviors ([@B2]; [@B7]; [@B10]). Sixth, depression is associated with negative cognitive changes including memory and executive function impairments ([@B13]; [@B128]; [@B149]), negative affect related to control, success, and rejection ([@B148]) and increased negative schema ([@B131]; [@B76]). As such, there is continuing pursuit of domains affected in MDD that can be linked to serotonergic function and genes. There is also interest in whether these dimensional features may define a more homogeneous subset for further exploration and targeted treatment. A short review of the relevant links of serotonin dysfunction in MDD and of potential multimodal intermediate phenotypes \[IPs ([@B12]; [@B51]; [@B134]; [@B72]; [@B142])\] is conducted to integrate these separate lines of inquiry.

Imaging Studies of 5-HT~1A~ Function
------------------------------------

Evidence of abnormal 5-HT (5-hydroxytyptamine refers to G protein coupled receptors and ligand-gated ion channels, also known as serotonin receptors) function in MDD is building, including for 5-HT~1A~ specifically (~1A~ is a subtype of 5-HT receptor which is the most widespread 5-HT receptor, including within cortex and medial temporal structures). Past human imaging studies of 5-HT~1A~ binding potential (BP) have focused on areas of binding where serotonin receptors are more densely populated, including the raphe, as well as frontal, cingulate and medial temporal cortices ([@B87]; [@B100]; [@B102], [@B101]; [@B24]; [@B123]; [@B58]). 5-HT~1A~ receptors regulate the firing of 5-HT neurons presynaptically in the raphe nuclei and are expressed postsynaptically in many different cortical and subcortical brain regions ([@B122]; [@B53]; [@B150]). In the cortex, there are inhibitory properties of the postsynaptic 5-HT~1A~ receptors ([@B30]; [@B10]), plus regulation of the release of glutamate in subcortical structures ([@B20]). A recent review of concentrations of transporter (5HTT), 5-HT~1A~, and 5-HT~2A~ receptors reflect the fact that 5-HTTs are densely populated in subcortical, pre-synaptic regions, whereas, 5-HT~1A~ and 5-HT~2A~ receptors are more dense in cortical regions ([@B59]; [@B54]). These same cortical areas support a number of cognitive and affective processes and both the regions and the processes they support are heavily implicated in MDD ([@B136]; [@B37]; [@B43]; [@B104], [@B105]; [@B24]; [@B66], [@B72], [@B68]; [@B108]; [@B23]).

Positron emission tomography (PET) studies, typically utilizing the selective radiotracer for 5-HT~1A~ receptors, ^\[11C\]^WAY-100635, have noted lowered levels of 5-HT~1A~ receptor availability (BP~ND~) within these regions in MDD as well as alterations in 5-HT~1A~ availability pre- and post-treatment ([@B8]; [@B24]; [@B92]; [@B39]; [@B55]). Lowered 5-HT~1A~ BP in MDD is the general pattern observed; however, utilizing arterial sampling or a cortical reference region can make a significant impact on the direction of effects \[higher or lower ([@B24]; [@B101])\]. As such, careful verification of reference region/marker equivalence between MDD and healthy comparison (HC) groups is important for PET studies with this radiotracer. Lower brainstem SERT BP was reported in an additional study of depressed suicide attempters ([@B98]). 5-HT~1A~ disruptions have also been reported in high-risk offspring of those with MDD ([@B90]).

Animal Models of 5-HT~1A~ in MDD
--------------------------------

Given the limited number and variability across human *in vivo* studies, we briefly review the role of 5-HT~1A~ in the pathophysiology of MDD as seen in animal models of depression and human postmortem studies. Animal studies have primarily reported increased 5-HT~1A~ function after chronic SSRI administration ([@B32]) and increases in anxious and depressive behaviors after 5-HT~1A~ blockade, depletion, or knockout ([@B99];[@B1]; [@B151]; [@B111]). Novel antidepressants including agomelatine and vortioxetine induced modulation of brain-derived neurotrophic factor (BDNF) which is a neurotrophin that serves as a survival factor for neurons ([@B84],[@B85]). In a related study, BDNF knock out mice showed a significant attenuation of 5-HT~1A~ receptor function ([@B38]). Acute stress results in decreased 5-HT~1A~ mRNA in the hippocampus ([@B81]) and those with knockout or blockade demonstrate memory dysfunction ([@B120]). Animals with 5-HT~1A~ antagonist acute injection into the dorsal raphe show enhanced social defeat behavior ([@B17]).

Stress-sensitive cynomolgus monkeys exhibit a reduced number of 5-HT~1A~ receptors in dorsal raphe after stress exposure ([@B77]). Similarly, exposure to peer-rearing in rhesus monkeys as an early life stressor generally results in lower *in vivo* 5-HT~1A~ receptor concentrations ([@B129]). Likewise, chronic psychosocial stress in tree shrews results in decreased 5-HT~1A~ receptors in prefrontal cortex, hippocampus, and parietal cortex ([@B27]).

Human Postmortem and Anatomical Studies
---------------------------------------

Furthermore, in human postmortem studies, lower hippocampal 5-HT~1A~ mRNA is demonstrated in MDD subjects, with death by accident, assault, suicide, or cardiac causes ([@B80]) and reduced 5-HT~1A~ receptors in amygdala and hippocampus in suicide completers ([@B15]). Finally, 5-HT~1A~ receptor density is related to gray matter volume cortical thickness in many prefrontal and parietal regions in HCs, but not in MDD ([@B107]; [@B150]). Notably, one recent study used PET binding to subdivide clusters in 5-HT function for anatomical parcellation and alignment with resting state networks ([@B54]). Both 5-HT~1A~ and 5-HT~2A~ demonstrate cortical; distribution and alignment with dorsal attention and frontoparietal networks (clusters 2 and 3), suggesting that is alignment between monamine function and cortical networks.

Tryptophan Depletion and Effects on Cognitive Control and Related Functions in MDD
----------------------------------------------------------------------------------

A potentially convergent line of study is a possibility that divergent serotonergic function for some individuals with MDD is related to abnormalities in executive function and affective processing -- these are broad domains within Research Domain Criteria \[RDoC ([@B19])\] that may constitute IPs for MDD. Executive functioning domains include conceptual reasoning, inhibitory control, verbal fluency, interference resolution, working memory -- components of the Cognitive Control network. Difficulties in these skills are present in MDD ([@B5]; [@B14]; [@B112]; [@B65]; [@B128]) and lead to work-related disability and productivity loss ([@B73]). Links between these executive function skills (and cognitive control network function) and serotonergic function are conducted by reducing synthesis of 5-HT centrally via ATD ([@B61]; [@B127]). ATD has also been shown to result in disrupted affective processing and networks ([@B104]), increasing negative emotional experience and decreases in positive affective experience \[[@B114]; [@B130]; [@B138]\]. ATD also disrupts social cooperation ([@B146]). Some affective domains of interest for MDD are enhanced memory for negative information and disrupted accuracy in processing of facial emotions \[[@B31]; [@B63], [@B65]; [@B42]\].

In summary, there is a distinct possibility that disrupted 5-HT~1A~ receptor mediated mechanisms might translate to affective and cognitive domains of dysfunction for MDD. Multimodal studies, encouraged by RDoC, can address convergence of multiple different assays. Here, we hypothesized that lower 5-HT~1A~ BP in MDD \[Hypothesis (Hyp) 1\] maybe related to dysfunction in affective (bottom-up, Hyp 2) and executive (top-down, Hyp 3) domains ([@B72], [@B68]; [@B23]). These affective dysfunction domains included negative memory bias, ([@B11]; [@B42]) and impaired emotion categorization ([@B31]; [@B63], [@B65]). We used executive dysfunction domains - previously identified factors in individuals with bipolar disease, similar to domains reported in MDD ([@B112]; [@B128]). These factors do not align perfectly with the RDoC domains within Cognitive Systems, although we note that the RDoC domains are suggestive and not prescriptive ([@B45]; [@B119]). The broader goal is to utilize dimensional, factor-driven analysis in studies where these are experimentally advantageous over DSM categories. Here, Cognitive Control subsumes the elements of (1) speed (Verbal Fluency and Processing Speed), (2) speed in the context of distracting or competing stimuli (Processing Speed with Interference Resolution), (3) stopping a prepotent response (e.g., regulation, here Inhibitory Control), and (4) balance of decision making within multistimulus sets and changing rules (Conceptual Reasoning and Set-Shifting) ([@B72]; [@B117]).

We further investigated relationships of fMRI BOLD responses during a Cognitive Control task based upon 5-HT~1A~ BP in the MDD sample, including fMRI BOLD responses based upon degree of 5-HT~1A~ BP~ND~ in the MDD sample \[Hyp 4 of lowered 5-HT~1A~ BP~ND~ correlated with lowered activation in Cognitive Control region(s)\]. Cross-modality comparisons are relatively rare in MDD (multimodal imaging can be simultaneous or on separate days), but they illustrate the value in integrating localization, function, and neurotransmitter density ([@B51]; [@B123]; [@B33]; [@B58]; [@B106]). Analyses were also conducted with the HC group to verify the general or MDD specific nature of these relationships (Hyp 5). Exploratory analyses with genetic variants related to serotonergic function were also conducted (Hyp 6) ([@B145]; [@B140]; [@B86]; [@B55]; [@B97]; [@B106]; [@B150]).

Materials and Methods {#s1}
=====================

Participants
------------

Twenty-nine HC and 25 patients with MDD were recruited via newspaper advertisements, campus fliers, and word of mouth with Institutional Review Board (IRB)--approved written informed consent consistent with the Declaration of Helsinki at the University of Michigan. Diagnosis was confirmed with the Structured Clinical Interview for Diagnostic and Statistical Manual \[DSM-IV ([@B3])\]. HC subjects were required to be below 5 and MDD subjects above 15 on the Hamilton Rating Scale for Depression for study entry \[HRSD, 17 item scale ([@B34])\], using conservative thresholds for sensitivity and specificity ([@B93]; [@B115]; [@B121]). The groups did not differ in age, sex, years of formal education, or intellectual ability \[([@B125]), all *p*'s \> 0.15, [Table 1](#T1){ref-type="table"}\]. Other evidence of neurological or psychiatric disorders, other than generalized anxiety and/or social/specific phobia, panic disorder in the MDD sample was exclusionary. Cigarette smokers and those with alcohol abuse or who had used illegal drugs in the past 2 years were excluded. Patients with MDD were unmedicated and had been medication-free for a minimum of 6 months for all potentially psychoactive medications (mean 25.7 months, 14 medication naïve).

###### 

Demographic and clinical information for participants with major depressive disorder and matching healthy control adults.

                         MDD (*N* = 25)   HC (*N* = 29)
  ---------------------- ---------------- ---------------
  Age                    39.7 (11.0)      37.8 (11.8)
  Education              15.0 (2.9)       16.1 (2.3)
  Shipley estimated IQ   101.8 (13.1)     105.6 (12.1)
  Sex                    14F, 11 M        18 F, 11M
  HDRS-17^∗^             19.0 (2.6)       0.9 (1.4)
  Suicide item (0--4)    0.5 (0.9)        --
  Neuroticism^∗^         60.3 (11.2)      40.2 (9.6)
  Comorbid anxiety Dx    11 (44%)         --
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-tests were used to compare groups for age, education, estimated IQ, HDRS, neuroticism. Chi-square was used to compare groups by sex distribution.

Overall Procedure
-----------------

Neuropsychological measures were typically captured within several days after the intake and diagnosis. fMRI and PET were collected on average 9.5 days (*SD* = 36.8) apart for participants. The SD is large because 2 MDD and 2 HC participants discontinued and then restarted the study about 3--4 months apart. 85% of participants completed all evaluations within 1 month.

PET Scanning and Processing Procedures
--------------------------------------

Positron emission tomography scanning was conducted using \[^11^C\]Way100635. PET procedures were similar to those described previously ([@B89]). PET images were acquired with a Siemens/CTI HR^+^ scanner in three-dimensional mode with septa retracted. \[carbonyl- 11C\]WAY-100635, a specific 5-HT~1A~ receptor antagonist, was synthesized at high specific activity ([@B44]). The tracer was administered as a bolus followed by continuous infusion to more rapidly achieve steady-state conditions. Eighteen scans of increasing duration (0.5--10 min) were acquired over a period of 90 min. Raw PET images were co-registered and smoothed with a Gaussian filter (4 mm FWHM). Smoothed images were transformed voxel-by-voxel into parametric maps of tracer transport (K~1~ ratio) and specific binding \[distribution volume ratio (DVR)\] using a modified Logan graphical analysis, with bilateral cerebellar white matter (excluding the vermis) as the reference region ([@B78]). Non-displaceable binding potential (BP~ND~) was defined as BP~ND~ = DVR-1 = k~2~B~max~/K~D~, where B~max~ is the total receptor concentration, K~D~ is the dissociation constant, and k~2~ is the extracellular concentration of tracer (assumed to be a small and constant value) ([@B131]). Two individuals (one control and one MDD) showed visible binding in the cerebellum and (as a result) anomalously low global BP~ND~ (2.4--3.0 SDs below the mean, illustrated in [Figure 1](#F1){ref-type="fig"}), and were excluded.

![Figure illustrating the 5-HT~1A~ BP values in the deep white matter (DWM) control region. Note that the two individuals (one MDD and one HC) with abnormally high binding potential (BP) in the cerebellar reference region resulted in low values in the DWM region. These two individuals were excluded from all analyses and the MDD and HC did not differ in DWM BP, indicating equivalence in the reference region. Further, no results were changed by including DWM BP as a covariate in analyses.](fpsyg-10-00691-g001){#F1}

Positron emission tomography images were coregistered with MRI images to allow anatomical localization of PET data. Coregistration was accomplished for each subject by alignment of K~1~ images with MRI SPGR images using co-registration within SPM2. MRI data were subsequently transformed into standardized coordinates (International Consortium for Brain Mapping; Montreal Neurological Institute) by linear and non-linear warping, and the resulting transformation matrix was applied to parametric PET images.

Although not central to the current study or hypotheses, we specifically addressed the concern that lowered 5-HT~1A~ BP~ND~ in MDD is a function of differences between HC and MDD in the cerebellar white matter reference region. Without an arterial reference point, we instead added a deep white matter (DWM) ROI within the centrum semiovale for test comparisons between MDD and HC subjects. This technique capitalizes on modeling DWM as a constant in the equation. Without any receptors, DWM would be a constant including noise -- the only variable free to vary in the equation is BP within the cerebellar white matter reference region (including noise). There were no significant differences between groups in 5-HT~1A~ BP~ND~ in the DWM of the centrum semiovale \[*t*(41) = 0.55, *p* = 0.59\]. The reference region BP was equivalent between groups, increasing confidence that effects reported herein are contingent upon inherent regional differences in BP between MDD and HC groups in the regions specified ([Figure 1](#F1){ref-type="fig"}).

Candidate Affective and Executive Domains Relevant to MDD
---------------------------------------------------------

The processing speed with interference resolution includes the trail making test, digit symbol substitution test, stroop color-word test, and response time to targets from the parametric go/no-go test. The parametric go/no-go test was programmed in EPrime 2 completed before the scanning session for practice ([@B62]; [@B64],[@B65],[@B66], [@B69]; [@B141]). It was also completed during fMRI. There are three levels of difficulty, including a 3 target Go-only condition, and 2 target alternating target Go/No-go condition, and a 2 target alternating target Go/No-go condition. There are 68 "lure" events so that correct and incorrect rejections of lures can be modeled and analyzed separately.

There are also less prominent potential domains/factors, less strongly linked to risk for MDD or BD, comprising Verbal Fluency with Processing Speed, Inhibitory Control, and Conceptual Reasoning and Set Shifting, and tests from these factors have been demonstrated to be dysfunctional in previous studies of MDD (see [@B71] for a review). Negative Memory Bias (NMB) was calculated as a subtraction of percentage of negative words recognized from the percentage of neutral words recognized from within the Emotion Words task programmed in EPrime 2 ([@B42]). In addition to the Negative Memory Bias, we also used performance accuracy in Emotion Classification of faces as potential Affective Processing domains in MDD that would be linked to abnormal 5-HT~1A~ BP~ND~ ([@B63]).

MRI for Co-registration of PET Images and Collection of fMRI BOLD
-----------------------------------------------------------------

One hundred twenty-four high-resolution SPGR axial anatomic images \[TE = 5 ms; TR (repetition time) = 24 ms, 45 degree flip angle, NEX (number of excitations) = 2, slice thickness = 1.2 or 1.3 mm, FOV = 24 cm, matrix size = 256 × 256\] were performed on each subject with a GE 3T Signa scanner for coregistration of PET images.

The Go/No-go task is a cognitive control task that has been used extensively by our group with fMRI, including in healthy aging, MDD, and bipolar disorder (for review, see [@B141]). The fMRI task includes event-related models for correctly responded "go" events or Hits, correctly rejected "no-go" events or Rejections, and incorrectly responded "no-go" events, or Commissions, modeled with the hemodynamic response function. The steps for processing the data and model building include slice timing, physiological correction, coregistration, normalization, smoothing with a 5 mm FWHM Gaussian filter, and building individual models using SPM2 as described previously ([@B66]). Contrasts were set up to define activation for Hits, Rejections, and Commissions in a fast event-related model. Imaging parameters include a TR of 2000 ms, FOV of 22 cm, with a 3.0 T GE Signa scanner using a standard radio frequency coil and T2^∗^- weighted pulse sequence. The images were collected using a forward-reverse spiral sequence with 29 axial slices of 4 mm.

Defining Regions of Significant Effect in 5-HT~1A~, and Low and Normal MDD Groups
---------------------------------------------------------------------------------

Differences between groups in 5-HT~1A~ BP~ND~ will be extracted from regions of significant effects (RSEs). 1st 5-HT~1A~ BP~ND~ levels will be converted to z scores based upon mean and standard deviation of BP~ND~ levels for the HC group for each RSE. Then the z scores will be averaged across all RSEs to create a mean Z Group RSE variable across all post-synaptic 5-HT~1A~ regions that differ between groups. Mean Z group RSE will be used as predictor variable in subsequent analyses with performance and fMRI IPs. We will use mean 5-HT~1A~ BP~ND~ PET results in RSEs to define low and normal 5-HT~1A~ BP~ND~ MDD groups in relation to HC 5-HT~1A~ BP~ND~ in the RSEs. These two MDD groups will then be compared to identify regions for fMRI analyses in the imaging contrasts (Commissions, Correct Rejections, Hits) for the Parametric Go/No-go test.

Genotyping for 5HTTLPR and MAO-A
--------------------------------

In addition, for exploratory purposes, the relative impact for *5-HTTLPR* and *MAO-A* genotype were evaluated, genes with a significant biological relationship with 5-HT~1A~ BP.

### 5HTTLPR

Genotyping protocols were performed according to [@B74]. The *5-HTTLPR* assay discriminates between two functional *5-HTT* promoter alleles, visualized as DNA bands of 528 bp and 484 bp (long and short alleles, l and s, respectively). Genotypes were grouped in accordance with *in vitro* data on a reduced transcriptional activity of the dominating s allele that leads to a decrease in central 5-HT turnover ([@B6]). Ten individuals did not have *5-HTTLPR* genotype obtained (6 HC, 4 MDD).

### MAO-A

Genomic DNA was purified from blood using standard methods. The *MAOA* promoter region that contains the upstream VNTR polymorphism ([@B118]) was amplified from 10 ng genomic DNA using the primer sequences: Forward 5 CCCAGGCTGCTCCAGAAACATG-3 and Reverse 5′-GTTCGGGACCTGGGCAGTTGTG-3′. Because of the high GC content in the VNTR region, amplification was performed using Invitrogen's PlatinumTaq and PCRX. Twenty-three individuals (12 HC, 11 MDD) did not have *MAO-A* genotype obtained.

Statistical Analyses
--------------------

First, we identified MDD specific regions of low 5-HT~1A~ BP~ND~ as described in the results section. We compared MDD and HC groups in 5-HT~1A~ BP~ND~ using a combined threshold of *p* \< 0.001 and a cluster minimum of 80mm^3^ was used between groups *t*-test in SPM2 ([Table 2](#T2){ref-type="table"} and [Figure 5](#F5){ref-type="fig"}). Mean 5-HT~1A~ BP~ND~ was extracted for these Regions of Significant Effects (RSEs) and BP~ND~ was used in group specific linear regressions in SPSS 22 with behavioral performance measures of affective processing (Negative Memory Bias, Emotion Categorization) and executive functioning (Processing Speed with Interference Resolution, Verbal Fluency with Processing Speed, Inhibitory Control, and Conceptual Reasoning and Set Shifting) factors/scores were evaluated as converging, multimodal candidate IPs using MANOVA in SPSS 22. fMRI BOLD activation differences were also investigated in SPM5 factorial model comparisons of normal and low 5-HT~1A~ BP~ND~ MDD groups based upon mean 1A BP~ND~ (with DWM BP as a covariate of no interest). Relationships between fMRI BOLD signal differences were evaluated subsequently with correlations with RDoC Domains scores in SPSS 22. These domains were also evaluated in exploratory analyses for serotonin-related genetic effects using *5-HTTLPR* and *MAO-A*.

###### 

Regions of significantly effect, with lower 5-HT~1A~ BP~ND~ in MDD relative to HC.

  Foci                BA   mm^3^   x     y     z     *Z*    *p*
  ------------------- ---- ------- ----- ----- ----- ------ ----------
  Uncus               20   1344    26    -5    -34   4.38   0.000034
  Hippocampus              1536    -25   -13   -20   4.24   0.000053
  Parahippocampal     35   1216    -32   -21   -19   3.96   0.00013
  Superior temporal   38   960     22    10    -37   4.17   0.000068
  Fusiform            37   2624    41    -62   -7    3.78   0.00023
  Precuneus           7    832     24    -69   33    3.66   0.00033

There were no regions where MDD group had greater BP relative to the HC group.

Results
=======

Defining Regions of Low 5-HT~1A~ Binding Potential in the MDD Group
-------------------------------------------------------------------

Regions of significant BP differences between HC and MDD groups (HC \> MDD) were used to define low 5-HT~1A~ BP~ND~ MDD regions of significant effect (hereafter RSE). The whole brain analyses in MDD vs HC with 5-HT~1A~ BP~ND~ indicated six RSEs of lower 5-HT~1A~ BP~ND~ in the MDD group relative to the HC group. These regions, predominantly temporal, are reported in [Table 2](#T2){ref-type="table"} and [Figure 5](#F5){ref-type="fig"}, defining 10--20% reduction in post-synaptic 5-HT~1A~ BP~ND~ in MDD across these regions. There were no regions where MDD group had greater BP~ND~ relative to the HC group. Half of the MDD group was below the 5th percentile of 5-HT~1A~ BP~ND~ for the Z normed average of the RSEs relative to the HC group.

Impact of Low 5HT1a BP~ND~ on Executive Functioning and Affective Processing IPs in MDD
---------------------------------------------------------------------------------------

We investigated the linear relationship of IPs (e.g., Processing Speed with Interference Resolution, Inhibitory Control, and Negative Memory Bias) with mean rank 5-HT~1A~ BP using regression in SPSS 22. Negative Memory Bias accounted for 16.4% (no difference after accounting for age) and Processing Speed with Interference Resolution accounted for 26.3% (35.4% after accounting for age effects) of mean rank BP~ND~ in the MDD group (covarying DWM DVR, *p'*s = 0.074, 0.029, respectively, [Figure 2](#F2){ref-type="fig"}). No other IPs were significantly related to mean rank 5-HT~1A~ BP~ND~ in the MDD group. In the control group, \<1% variance in processing speed with interference resolution or negative memory bias was accounted for by mean rank BP~ND~. Negative memory bias and processing speed with interference resolution were non-significantly correlated (*r* = -0.33, *p* = 0.17).

![Relationships of Negative Memory Bias (NMB) and Processing Speed with Interference Resolution (PSIR) variables with mean rank 5-HT~1A~ BP in the MDD group.](fpsyg-10-00691-g002){#F2}

Lowered Mean 5-HT~1A~ BP in Relation to fMRI BOLD Responses to Hits, Rejections, and Commissions Within the MDD Group
---------------------------------------------------------------------------------------------------------------------

It was expected that abnormalities in executive functioning domains based upon mean 5-HT~1A~ BP~ND~ would also be related to BOLD fMRI differences. As this has not been evaluated in published studies, there was no clear expectation of hyper or hypo (our hypothesis) activation during the Cognitive Control task for low vs normal 5-HT~1A~ BP groups. These contrasts in SPM5 included in separate models for BOLD responses during Hits, Correct Rejections, and Commissions. Rejections and Commissions are used to calculate Inhibitory Control, which would be expected to be related to 5-HT~1A~ BP~ND~ based upon relationships illustrated in [Figure 3](#F3){ref-type="fig"}. Processing speed with interference resolution includes response speed to Hits and Conceptual Reasoning with Set Shifting includes Hit accuracy, suggesting that these Hit events should also be related to 5-HT~1A~ BP~ND~. There were some individuals without fMRI scans, some with abnormal DVR in the cerebellum (see section "Materials and Methods"), and some with low IQ, leaving, 17 MDD subjects available for fMRI analyses (divided into normal and low, in a model with 19 HCs). Whole brain analyses were conducted using combined height and extent thresholds with 3dClustSim (*p* \< 0.005, *k* \> 55, 1000 Monte Carlo simulations, *p* \< 0.05 whole brain adjusted).

![Figure illustrates significant BOLD activation relationships with 5HT-1a BP in the MDD group. There was greater BOLD activation with normal 5-HT~1A~ BP MDD in the Parametric Go/No-go test. This is shown for correct Hits (Panel **C,D**, cyan), for Commissions (Panel **B**, red), Correct Rejections (Panels **C,E**, yellow). There were also a few areas of greater activation for correct Hits with low 5-HT~1A~ BP in the MDD group (Panels **A,D**, green).](fpsyg-10-00691-g003){#F3}

Within the MDD sample, there was a general pattern of greater activation with increasing mean 5-HT~1A~ BP~ND~. For Correct Rejections (yellow, [Figure 3](#F3){ref-type="fig"}, Panels C, E), this was observed in dorsal anterior cingulate, postcentral gyrus, left posterior insula, and mid cingulate gyrus RSEs. There was increasing activation in rostral anterior cingulate, left inferior frontal gyrus, bilateral dorsal medial thalamus, and pulvinar RSEs with greater mean 5-HT~1A~ BP~ND~ in relation to Commissions. There was greater activation for Hits in a left posterior insula RSE related to mean 5-HT~1A~ BP~ND~ (cyan, [Figure 3](#F3){ref-type="fig"}, Panel C). The exception to this general pattern of increased activation with increasing mean 5-HT~1A~ BP in MDD was observed for Hits in bilateral superior parietal lobule and right anterior inferior frontal gyrus, where there was decreasing activation as mean 5-HT~1A~ BP~ND~ increased (green, [Figure 3](#F3){ref-type="fig"}, Panels A and D).

We further investigated dimensional, linear links between these multimodal IPs using pairwise correlations between the mean rank 5-HT~1A~ BP~ND~, mean rank for the combined fMRI BOLD RSEs (by condition), and behavioral performance parameters. These fMRI BOLD RSE clusters were combined by condition and group difference for purposes of data reduction, with the resulting mean Z BOLD RSE scores highly correlated with all individual clusters (*r*'s \> 0.59 for Commission clusters, *r*'s \> 0.68 for Correct Rejection clusters, *r*'s \> 0.78 for Hits clusters, *p*'s \< 0.001). As illustrated in [Figure 4](#F4){ref-type="fig"}, the mean Z fMRI BOLD RSEs were significantly correlated with mean rank 5-HT~1A~ BP for Hit BOLD RSE Normal \> Low (*r* = 0.73, *p* \< 0.001, [Figure 4](#F4){ref-type="fig"}, Panel A), Hits mean Z BOLD RSEs Low \> Normal (*r* = -0.80, *p* = 0.0001, Panel B), Commissions mean Z BOLD RSEs Normal \> Low (*r* = 0.87, *p* = 0.0001, Panel E), and Rejections mean Z BOLD RSEs Normal \> Low (*r* = 0.77, *p* = 0.0001, Panel C). PSIR Z score was positively correlated with fMRI BOLD Hit RSE (Normal \> Low, *r* = 0.54, *p* = 0.02) and fMRI BOLD Commission mean Z RSEs (Normal \> Low, *r* = 0.53, *p* = 0.03, Panel F). Negative Memory Bias Z was significantly positively correlated with fMRI BOLD Hit mean Z RSEs (Low \> Normal, *r* = 0.50, *p* = 0.04) and negatively with fMRI BOLD Rejections mean Z RSEs (Normal \> Low, *r* = -0.59, *p* = 0.01, Panel D). Information from 19 HCs with all modalities of measurement included -- are added to these scatterplots ([Figure 4](#F4){ref-type="fig"}) for comparison. The scatterplots indicate individual level differences in fMRI for Cognitive Control that relate to 5-HT~1A~ BP~ND~ and PSIR.

![Illustration of linear relationships by group for 5-HT~1A~ BP, fMRI BOLD signal, and neuropsychological performance measures (MDD in black, HC in gray, dashed line for both). Panel **A** shows the relationship between BOLD activation or Hits in left posterior insula with mean 5-HT~1A~ BP rank. Panel **B** illustrates the relationship between mean BOLD signal RSEs for correct Hits that are greater in normal relative to lower 5-HT~1A~ BP in MDD with mean 5-HT~1A~ BP rank. Panel **C** depicts the relationship between mean BOLD for correct rejections and mean 5-HT~1A~ BP rank. The relationship between mean BOLD for correct rejections and NMB in shown in Panel **D**. Panel **E** illustrates the mean BOLD for commission errors with mean 5-HT~1A~ BP rank. The relationship between mean BOLD for commission errors and processing speed with interference resolution is shown in Panel **F**.](fpsyg-10-00691-g004){#F4}

Exploratory Analyses of *5-HTTLPR* and *MAO-A* Effects in Executive Functioning and Affective Processing IPs
------------------------------------------------------------------------------------------------------------

Next, we expected that the low functioning forms of either the *MAO-A* and *5HTTLPR* genotypes would be associated with poorer performance irrespective of group for candidate genes in exploratory analyses. Given the small sample size, and the relatively weak link between Cognitive/Affective IPs and functional polymorphisms that might impact 5-HT~1A~, the probability of type II error is high. The MANCOVA for *5-HTTLPR* (diagnosis as covariate) was significant for Conceptual Reasoning and Set Shifting \[*F*(1,29) = 4.29, *p* = 0.047, *E*^2^ = 0.13\] and Processing Speed with Interference Resolution \[*F*(1,29) = 5.93, *p* = 0.02, *E*^2^ = 0.17\], with poorer performance in *s* allele carriers irrespective of group status. For definition of high and low functioning *MAO-A* genes, the intermediate genotype group of women was placed into the low functioning allele group based upon prior results ([@B5]) There was a significant effect for genotype on Conceptual Reasoning and Set Shifting \[*F*(1,26) = 5.73, *p* = 0.02, *E*^2^ =0 .18\] and a trend for Emotion Categorization \[*F*(1,26) = 3.35, *p* = 0.08, *E*^2^ = 0.11\]. Those with low function alleles for *MAO-A* performed better on Conceptual Reasoning and Set Shifting and marginally worse on Emotion Categorization.

5-HT~1A~ BP~ND~ Links to *5-HTTLPR* Genotype and Relationship With PSIR
-----------------------------------------------------------------------

Next, we evaluated specifically the effect of *5-HTLPPR* genotype on 5-HT~1A~ BP~ND~ reductions, covarying for disease group. Group results based upon disease (from [Table 2](#T2){ref-type="table"}) and genotype are displayed in [Figure 5](#F5){ref-type="fig"} (Panels A and B). Those with the *5-HTTLPR s* allele, irrespective of disease status, exhibited lower 5-HT~1A~ BP~ND~ in fronto-temporal regions, overlapping with temporal regions that were lower in those with MDD. There were additional frontal regions of lower 5-HT~1A~ BP~ND~ in *s* allele carriers irrespective of diagnosis.

![Areas of greater 5-HT~1A~ BP in HC relative to MDD (blue) and in *l* homozygotes for *5-HTTLPR* relative to *s/s or l/s* (red) in Panels **A,B**. Note that the blue clusters are the same as those listed in [Table 2](#T2){ref-type="table"}, which were used to define the regions of significant effect that defined mean rank BP regressors. They are included for comparison with the *5-HTTLPR* analysis here to show the similarities in location and direction. Panel **C** depicts the actual and predicted PSIR values. The predictions are based upon mean 5-HT~1A~ BP values from the regions of significant effect (RSEs) in the *5-HTTLPR* analysis.](fpsyg-10-00691-g005){#F5}

Mean rank order BP based upon *5-HTTLPR* was averaged across all 16 RSEs of greater BP in *l/l* homozygotes relative to the *s* allele carriers. Regression was used to predict Processing Speed with Interference Resolution based upon *5-HTTLPR* and also using mean rank BP from the *5-HTTLPR* RSEs. Fifty-two percent of Processing Speed with Interference Resolution was explained by 5-HT~1A~ BP~ND~ regions with significantly low BP extracted in those with an *s* allele (covarying age and DWM DVR, *B* = 0.79, *p* = 0.001, [Figure 5](#F5){ref-type="fig"}, Panel C). 5-HT~1A~ RSEs defined by MDD vs control and by *5-HTTLPR* were highly correlated (*r* = 0.88, *p* \< 0.001) in 5-HT~1A~ BP~ND~. MDD and *5-HTTLPR s* allele were retained as independent variables in this analysis. No other regression models reached significance when using mean rank BP from the *5-HTTLPR* RSEs to predict Negative Memory Bias, Emotion Categorization, Inhibitory Control, or Conceptual Reasoning with Set Shifting.

Discussion
==========

The present study is the first to link abnormal 5-HT~1A~ BP~ND~ measures in unmedicated, symptomatic patients with MDD to objective performance and imaging markers of illness, in this case interference resolution, a component of Cognitive Control. The separation of interference resolution performance by 5-HT~1A~ levels is marked, with a medium-large effect size. The abnormal 5-HT~1A~ BP~ND~ is also related to fMRI BOLD hypoactivation changes in a Cognitive Control domain during Inhibitory Control, the Parametric Go/No-Go Test. The impact of *5-HTTLPR* genotype upon interference resolution and 5-HT~1A~ is modest and significant. The results follow previous studies showing links between 5-HT~1A~ BP~ND~ values with clinical factors such as anxiety symptoms, treatment outcome, genetics, and sex ([@B8]; [@B24]; [@B39]; [@B91]; [@B101]). There is also evidence that lower 5-HT~1A~ levels are present when there are increased depression symptoms in the context of epilepsy, Parkinson disease and in chronic stress without depression ([@B49]). Using objective, but simpler, performance measures to identify subjects with a higher probability of abnormal 5-HT~1A~ BP~ND~ could have substantial benefits for clinical, genetic and research studies. The executive functioning measures used to derive the processing speed with interference resolution variables are inexpensive to administer and are easily employed in subject recruitment (even clinical) settings ([@B65]; [@B22]). These measures could be used to select individuals for treatments or research protocols that specifically target 5-HT~1A~ receptor functioning and for subtype-specific pharmacotherapy treatment trials. Analogs of these performance measures are already present in animal models to further aid in strategies for better understanding the neurobiology and genetics of depression and for new treatment development.

In the data presented it was striking that Cognitive Control, and not Negative Memory Bias (inverted effect) or Emotion Categorization, was related to lower 5-HT~1A~ BP~ND~ in MDD. Indeed, recent studies have demonstrated that executive functioning measures, an umbrella domain term that includes Cognitive Control, are perhaps most critical in understanding increased risk for MDD, and are observed in the remitted state, and in family relatives of those with mood disorders ([@B16]; [@B9]; [@B103]). A recent review illustrated how executive dysfunction for those with MDD is substantial and fairly consistent across well-powered studies ([@B112]). Some existing literature, although mainly with small N studies, suggest that executive functioning is also a good predictor of treatment response and functioning in MDD ([@B52]; [@B135]; [@B47]; [@B22]). Executive functioning also can be used to predict recurrence ([@B69]) and workplace disability ([@B73]).

A recent review of 5-HT~1A~ receptor studies suggested that there is a weak relationship between 5-HT~1A~ and cognitive function ([@B10]). One of four studies in healthy controls have illustrated a relationship between 5-HT~1A~ BP~ND~ and cognitive performance ([@B147]). A pilot study in those with Alzheimer's disease, mild cognitive impairment (MCI), or neither suggested a relationship of decreased 5-HT~1A~ BP~ND~ with poorer MMSE in the entire sample, and with learning and memory in the healthy control and MCI participants ([@B56]). Another study suggests that gray matter thickness in key limbic regions is positively associated with 5-HT~1A~ ([@B60]). A similar study shows these associations in fronto-limbic regions ([@B150]). In our control sample we replicate the pattern of non-significant relationships of 5-HT~1A~ BP~ND~ to cognitive and affective measures. However, in MDD, we demonstrate a significant positive relationship of 5-HT~1A~ with Negative Memory Bias and Inhibitory Control, and a significant negative relationship of 5-HT~1A~ with Processing Speed with Interference Resolution.

fMRI BOLD signal changes for correct rejections and errors of commission resulted in hypoactivation in critical regulatory and inhibitory regions for those with lower 5-HT~1A~ BP~ND~. These low BOLD signals were related to Negative Memory Bias and Processing Speed with Interference Resolution. Notably, those MDD with lower 5-HT~1A~ BP~ND~ levels show increasing difficulties with poorer set-shifting and processing speed. In contrast and with an intriguing result, MDD subjects with higher/normative 5-HT~1A~ BP~ND~ levels exhibited significant Negative Memory Bias and increased activation in regulatory regions during successful rejection. As a result, increased need for recruitment in the mid-dorsal and rostral anterior cingulate for successful rejection may reflect poorer Inhibitory Control in those without lower 5-HT~1A~ BP~ND~ levels. This observation is confirmed by performance above normal levels in Inhibitory Control as 5-HT~1A~ BP~ND~ levels decreased. Those with higher/normative5-HT~1A~ BP~ND~ 5-HT~1A~ BP~ND~ levels tended to have worse Negative Memory Bias, Inhibitory Control, and increased BOLD recruitment for successful rejection of prepotent stimuli. Although the sample is quite small, these results reaffirm with other work that there likely many circuits, neurotransmitters, and behaviors associated with subtypes of MDD that are heretofore unclear ([@B142]; [@B57]).

Further, *5-HTTLPR* appears to be related to both 5-HT~1A~ BP~ND~ levels, and executive functioning performance, irrespective of illness. Notably, samples of this small size often suffer from difficulty with replication and should be interpreted very cautiously. There are some clues, however, that interference resolution might explain the inconsistent findings in emotion processing studies of *5-HTTLPR* from other studies as well. For example, affective processing and executive regulation can be in dynamic opposition to one another in some contexts, or in the case of psychiatric illness, there may be excessive responses in the former *and* weaker control in the latter ([@B104]; [@B52]; [@B66], [@B68]). Presence of the low functioning alleles of *5-HTTLPR* may reflect a relatively weaker executive functioning system, resulting in a stronger environmental dependence in the development of and execution of emotion regulation ([@B46]; [@B21]; [@B79]; [@B106]). In non-stressful environments, this weakness is less likely to result in problematic outcomes, but could still result in excessive responses to negative emotional stimuli ([@B124]; [@B132]). This pattern of diminished regulation skill in those carrying the short allele may be exaggerated in MDD ([@B21]). In high demand, high stress, negative environments, there may be greater difficulty in regulating negative emotional responses, and greater difficulty in shifting from one emotional state to another for those with low functioning *5-HTTLPR* alleles ([@B46]; [@B95]; [@B106]). The lack of regulation or emotional flexibility to environmental demands could then perpetuate depressive symptoms.

Use of screening tools like PSIR measures, with knowledge of convergent results with the 5-HT~1A~ BP~ND~ levels may be one dimensional way of increasing the homogeneity in MDD samples. Such increased homogeneity could lead to more targeted, precision medicine trials. For example, preselecting individuals based upon poor Cognitive Control could lead to a larger percentage with low 5-HT~1A~ BP~ND~, facilitating identification of related biomarkers for treatment. As we already know that weaker CC is a predictor of poor treatment response, greater likelihood of recurrence, these individuals might benefit from different treatment algorithms \[e.g., TMS trials ([@B52]; [@B48]; [@B126]; [@B66],[@B67], [@B69],[@B70]; [@B75]; [@B25]; [@B18]; [@B22]; [@B94])\].

It is also notable that Emotion Categorization accuracy, although related at a trend level to MAO-A genotype, was not related to 5-HT~1A~ BP~ND~ levels or *5-HTTLPR*. More surprisingly, higher mean rank BP was associated with *greater* Negative Memory Bias in MDD. Those with lower 5-HT~1A~ BP~ND~ exhibited no evidence of a Negative Memory Bias, suggesting that using mean rank BP to illustrate dimensional functioning in MDD could be defined in part by the segregation of Affective and Executive Domains. In reality, though, risk for MDD is likely defined by affective dysfunction, executive dysfunction, *or* dysfunction in both systems, and it is unlikely to be so clearly illustrated based upon results from one ligand. Several recent studies reported mixed results in links between serotonin genes and emotion reactivity ([@B58]; [@B106]).

The main limitation of the study is the sample size. We were able to obtain a relatively large sample for a multimodal study, and we were also able to find strong biological links between different measurement modalities. Samples of this size only reliably find large and very large effect sizes. We did obtain robust results consistent with our hypotheses. Another potential limitation of the present study relates to the broader difficulty within the field to agree upon the best reference strategy for calculating 5-HT~1A~ BP~ND~. Although we have shown equivalence in our reference region between groups. There are challenges to the reference region approach that appear to be surmountable by excluding gray matter and vermis, such as in this work ([@B101]), and verifying equivalence of the reference region, as we have done. Animal models, especially those of 5-HT~1A~ knockout mice, suggest that there may be lower 5-HT~1A~ availability in MDD and similar states, resulting in decreased serotonergic regulation. Likewise, postmortem data also suggests decreased 5-HT~1A~ mRNA in MDD. These findings are contrasted with others suggesting that higher 5-HT~1A~ in mice can mimic aspects of autism and not anxiety/depression. We contend that the present results strengthen evidence that lower 5-HT~1A~ BP~ND~ is a viable IP in MDD. This is in part upon the clear lack of BP difference in a deep white matter region, the presence of a behavioral performance correlate, links to fMRI BOLD, and link to a genetic marker *5-HTTLPR*. At the very least, the fact that 5-HT~1A~ BP~ND~ is altered in some individuals with MDD is clear. Until the discrepant reference region/correction methods can be resolved, directionality is still contested. Individual studies will have to demonstrate equivalence of reference ranges/structures. Furthermore, newer radioligands such as ([@B26]) MPFF might have more sensitive and stable properties for investigation of 5-HT~1A~ BP~ND~ with MDD subjects absent these reference region concerns ([@B82]).

In addition, fMRI is expensive and requires extensive equipment for set-up and analysis. A lower cost alternative to measure hemoglobin changes during task may be functional near-infrared spectroscopy (fNIRS) ([@B40]). As a number of the imaging regions identified here were cortical, it is possible that fNIRS could be used less expensively and with a broader range of patients to understand the relationship of hemodynamic changes to lowered 5-HT~1A~ function and cognitive control ([@B88]). Finally, neuropsychological testing, fMRI and PET were typically collected on separate days and locations. The anatomical cross-localization could be off in such instances, and the measurements could be weakened by day-session specific parameters ([@B123]; [@B33]). As the relationships were quite robust, there may have been additional links that were missed.

5-HT~1A~ function has a number of associations with other chronic diseases that are often comorbid with MDD, including coronary artery disease and obesity ([@B139]; [@B110]; [@B109]; [@B41]), and changes in 5-HT~1A~ function are coassociated with changes in pro-inflammatory cytokines including interleukin-1 beta (IL-1β), IL-17, and tumor necrosis factor -- alpha (TNF-α) ([@B4]; [@B83]; [@B96]). These studies suggest that 5-HT~1A~ shares functions that are related to, but extend beyond the phenotype of MDD, which in light of the present study, further confirms a need for homogeneous subsets that can be used to explore specific biological pathways for illness and recovery.

Conclusion
==========

In conclusion, the present study offers promising new evidence that biomarkers for MDD can be found and objectively measured. The heterogeneity of MDD has been problematic in pursuing these biomarkers, and identification of subtypes of MDD may, in the end, prove to be the most fruitful in linking biomarkers, to phenotypes, to genetic risks, and ultimately to personalized medicine. The phenotypic heterogeneity of MDD, combined with prior attempts at a "one size fits all" biomarker approach to MDD has been one limiting factor in this complex illness. Future work can capitalize upon the relationship between 5-HT~1A~ BP~ND~ abnormalities and executive functioning in MDD. These links could also be pursued more broadly in other psychiatric conditions within the RDoC initiative, as executive functioning disruption is not specific to MDD.
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